 | Up a level |
Ashton, N. J., Leuzy, A., Karikari, T. K., Mattsson-Carlgren, N., Dodich, A., Boccardi, M., Corre, J., Drzezga, A., Nordberg, A., Ossenkoppele, R., Zetterberg, H., Blennow, K., Frisoni, G. B., Garibotto, V. and Hansson, O. (2021). The validation status of blood biomarkers of amyloid and phospho-tau assessed with the 5-phase development framework for AD biomarkers. Eur. J. Nucl. Med. Mol. Imaging, 48 (7). S. 2140 - 2157. NEW YORK: SPRINGER. ISSN 1619-7089
Caroli, A., Prestia, A., Galluzzi, S., Ferrari, C., van der Flier, W. M., Ossenkoppele, R., Van Berckel, B., Barkhof, F., Teunissen, C. E., Wall, A., Carter, S. F., Scholl, M., Choo, I. H., Grimmer, T., Nordberg, A., Scheltens, P., Drzezga, A. and Frisoni, G. B. (2014). Mild cognitive impairment with suspected non AD pathology (SNAP): prediction of progression to dementia. J. Neurol., 261. S. S14 - 1. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1432-1459
Caroli, A., Prestia, A., Galluzzi, S., Ferrari, C., van der Flier, W. M., Ossenkoppele, R., Van Berckel, B., Barkhof, F., Teunissen, C. E., Wall, A., Carter, S. F., Scholl, M., Choo, I. H., Grimmer, T., Nordberg, A., Scheltens, P., Drzezga, A. and Frisoni, G. B. (2014). Mild cognitive impairment with suspected non AD pathology (SNAP): prediction of progression to dementia. Eur. J. Neurol., 21. S. 19 - 20. HOBOKEN: WILEY-BLACKWELL. ISSN 1468-1331
Herholz, K., Nordberg, A., Salmon, E., Perani, D., Kessler, J., Mielke, Rüdiger, Halber, M., Jelic, V., Almkvist, O., Collette, F., Alberoni, M., Kennedy, A., Hasselbalch, S., Fazio, F. and Heiss, W.-D. (1999). Impairment of Neocortical Metabolism Predicts Progression in Alzheimer’s Disease. Dementia and Geriatric Cognitive Disorders, 10 (6). pp. 494-504. Karger. ISSN 1420-8008
Leuzy, A., Ashton, N. J., Mattsson-Carlgren, N., Dodich, A., Boccardi, M., Corre, J., Drzezga, A., Nordberg, A., Ossenkoppele, R., Zetterberg, H., Blennow, K., Frisoni, G. B., Garibotto, V. and Hansson, O. (2021). 2020 update on the clinical validity of cerebrospinal fluid amyloid, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework. Eur. J. Nucl. Med. Mol. Imaging, 48 (7). S. 2121 - 2140. NEW YORK: SPRINGER. ISSN 1619-7089
Wolters, E. E., Dodich, A., Boccardi, M., Corre, J., Drzezga, A., Hansson, O., Nordberg, A., Frisoni, G. B., Garibotto, V and Ossenkoppele, R. (2021). Clinical validity of increased cortical uptake of [F-18]flortaucipir on PET as a biomarker for Alzheimer's disease in the context of a structured 5-phase biomarker development framework. Eur. J. Nucl. Med. Mol. Imaging, 48 (7). S. 2097 - 2110. NEW YORK: SPRINGER. ISSN 1619-7089